Mometasonfuroat Aristo (Mometasone Furoate Ph. Eur.)

Mometasone furoate, the active ingredient in Mometasonfuroat Aristo, is a corticosteroid presented as a nasal spray formulation for intranasal use. It is indicated for the treatment of allergic rhinitis and related nasal inflammation in adults and children. GNH USA supplies Mometasonfuroat Aristo as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Mometasone furoate nasal spray acts on the inflammatory pathways of the nasal mucosa to relieve allergic symptoms. - Allergic rhinitis (seasonal): alleviates nasal congestion, sneezing and itching. - Allergic rhinitis (perennial): reduces chronic nasal inflammation and discharge. - Nasal symptoms due to environmental allergens: improves overall nasal airflow and comfort.

Mometasone furoate nasal spray may cause local and systemic adverse reactions.

Common Side Effects: - Nasal irritation or burning sensation - Epistaxis (nosebleed) - Headache - Throat irritation or dryness - Altered taste or bitter taste - Cough

Serious or Rare Side Effects: - Nasal septal perforation - Severe allergic reaction (anaphylaxis) - Vision changes or cataract formation - Adrenal suppression with prolonged high‑dose use - Opportunistic fungal infection of the nasal passages

Before using Mometasonfuroat Aristo, consider the following precautions. - Pregnancy: consult a healthcare provider before initiating therapy. - Breastfeeding: discuss potential risks with a physician. - Concomitant nasal surgery or trauma: postpone use until the nasal cavity has healed. - Long‑term therapy: monitor for signs of systemic corticosteroid exposure, such as growth suppression in children. - Use only as directed: avoid exceeding the prescribed frequency to minimize local irritation. - Store at room temperature: keep in the original container, protect from moisture and heat.

Mometasone furoate nasal spray can interact with other medications.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase systemic corticosteroid exposure. - Live vaccines: reduced vaccine efficacy and increased infection risk. - Systemic corticosteroids: additive immunosuppressive effects.

Moderate Interactions (Monitor Closely): - Antifungal azoles and macrolide antibiotics: may modestly raise local drug levels. - Protease inhibitors (e.g., ritonavir): potential increase in corticosteroid concentration.